Description
Femoston (Estradiol/Dydrogesterone) Coated Tablets 1 mg/10 mg. №28
Ingredients:
Each coated tablet contains 1 mg of estradiol and 10 mg of dydrogesterone.
Mechanism of Action:
Femoston combines estradiol, an estrogen hormone, with dydrogesterone, a progestogen. Estradiol helps to alleviate menopausal symptoms by replacing the natural estrogen that the body no longer produces in sufficient amounts. Dydrogesterone complements estradiol by protecting the uterus from potential estrogen-induced risks, maintaining the endometrium’s health.
Pharmacological Properties:
The combination of estradiol and dydrogesterone in Femoston provides comprehensive hormone replacement therapy benefits. Estradiol acts on estrogen receptors, exerting its effects on various tissues, while dydrogesterone supports the endometrium’s stability without adversely affecting the beneficial effects of estradiol.
Indications for Use:
Femoston tablets are specifically indicated for hormone replacement therapy in postmenopausal women with an intact uterus to relieve menopausal symptoms and prevent associated complications.
Contraindications:
Avoid using Femoston if you have a history of hormone-sensitive cancers (e.g., breast cancer), liver disease, undiagnosed vaginal bleeding, or a known hypersensitivity to any of the components in the tablets.
Side Effects:
Common side effects of Femoston may include breast tenderness, headache, nausea, and breakthrough bleeding. Contact your healthcare provider if you experience any persistent or severe side effects while taking this medication.
Usage Instructions:
Take one tablet orally once daily, preferably at the same time each day. Swallow the tablet whole with a glass of water. Follow the dosage instructions provided by your healthcare professional for optimal therapeutic outcomes.
Benefits Compared to Analogues:
Femoston offers the advantage of combining estradiol with dydrogesterone, providing a balanced hormone replacement therapy option that minimizes the risk of endometrial hyperplasia associated with estrogen-alone therapy. This combination therapy offers effective symptom relief while maintaining uterine health.
Suitable Patient Groups:
Femoston is suitable for postmenopausal women with an intact uterus seeking hormone replacement therapy. It is essential to consult with a healthcare provider to determine the appropriateness of Femoston for individual cases, including considerations for children, the elderly, or other specific patient populations.
Storage Conditions and Shelf Life:
Store Femoston in a cool, dry place away from direct sunlight and moisture. Keep the tablets in their original packaging to protect them from environmental factors. Check the expiration date on the packaging and do not use the product if past the indicated shelf life.
Packaging Description:
Femoston is available in blister packs containing 28 coated tablets. Each tablet is individually sealed to maintain its integrity and potency. The packaging should include essential information such as the product name, dosage strength, ingredients, and usage instructions.
Scientific Evidence:
Estradiol and dydrogesterone in Femoston have been extensively studied for their efficacy in managing menopausal symptoms and preventing osteoporosis. Research published in the Journal of Menopause demonstrated that estradiol therapy significantly improved vasomotor symptoms and quality of life in postmenopausal women.
Additional Information:
Discuss the risks and benefits of hormone replacement therapy with your healthcare provider before initiating Femoston treatment. Regular monitoring is crucial to ensure the therapy’s safety and effectiveness. Studies have shown that Femoston offers a well-tolerated and effective option for managing menopausal symptoms, with a lower risk of endometrial hyperplasia compared to estrogen-alone therapy. Consult your doctor for personalized advice on hormone replacement therapy.
